amgen glp-1 obesity drug market potential 2025 Anti-Obesity Outlook 2025–2032: Strong CAGR of 18.01% with USD 82.55 Billion Valuation Pharma Giants Bet on Next-Generation
Description
PMC 7376989
Whether this area could expand to have single small molecules that target multiple receptors remains to be seen
Novel providers such as gyms/ weight management centers have emerged by incorporating GLP-1 medications
Post-marketing surveillance and case reports have documented instances of acute pancreatitis in patients taking these medications, prompting regulatory agencies to investigate the association
Recently, it was confirmed that GLP-1 receptor agonists consistently reduce number of atherothrombotic events and have positive effects on kidney function in patients with type 2 diabetes (30)
Zhou, X
